In this study, the group of Pilar Martín-Duque showed that a nanoscale vector based on ultrasmall PtNPs and exosomes exhibits antitumoral properties comparable or higher to those of the FDA approved cisplatin. They demonstrated their anticancer properties both in vitro and in vivo comparing the results obtained with the administration of equivalent amounts of cisplatin, […]
Read MoreA new participation at ISEV #EVClub in which Carmen Campos and Mar Valés-Gómez have presented their work on developments for detection of EVs from different biofluids https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-022-01256-5 You can find this interesting video at https://www.youtube.com/watch?v=CzR9OnSjpeg
Read MoreDear GEIVEX members, The second round of 2022 GEIVEX Mobility Fellowships is now open! These fellowships provide funding to promote exchange visits between laboratories, to strengthen EV-driven research and collaboration between institutions to contribute to the development of high quality research on Extracellular Vesicles by members of our non-profit organization. They are particularly intended for […]
Read MoreThe Nano-Immuno-Therapies Unit (https://cristinafornaguera.eu), from the Group of Materials Engineering (Gemat), at IQS-URL (Barcelona) is looking for a motivated junior postdoc. The group is focused on the design of advanced nano-delivery systems encapsulating nucleic acids, for their use as mRNA vaccines. Our nanoformulations include from polymeric nanoparticles, using proprietary polymers to engineered extracellular vesicles. You […]
Read MoreEstimados Socios de GEIVEX, Nos complace anunciar la Asamblea General Anual de Socios de GEIVEX que tendrá lugar en Santiago de Compostela, el 27 de octubre a las 17.10 horas en el Auditorio de la Facultad de Medicina, sede del Simposio, para discutir las nuevas iniciativas organizadas por nuestra Asociación. Nuestra agenda incluye: Bienvenida por […]
Read MoreThe group of Dr Vicent describe a rapid, convergent, and cost-efficient strategy to analyze candidate U.S. Food and Drug Administration (FDA)-approved drugs that inhibit exosome release and/or biogenesis using breast cancer cell line models in the hope of repurposing them for the clinical treatment of metastatic tumors based on AlphaScreenTM technology The manuscript is available at […]
Read MoreA collaborative work from Dr Borrás´s and Dr Falcón-Perez groups demonstrating the functional relevance of N-Glycans on the surface of EVs. The manuscript is available at https://www.mdpi.com/1422-0067/23/17/9539
Read MoreEl biobanco de la Fundación Instituto Valenciano de Oncología (IVO), ha sido el primero en España en obtener la acreditación internacional ISO20387: una norma que avala la gestión de la calidad del material biológico, de las muestras de control y los datos obtenidos para la investigación biomédica. Para el jefe de servicio del laboratorio de […]
Read More